Skip to main content

PIK3CA

Videos

Anna Martling, MD, Karolinska Institutet
Videos
01/28/2025
Anna Martling, MD, PhD, discusses study results which found that adjuvant daily aspirin reduced the risk of colorectal cancer recurrence among patients with PI3K alterations.
Anna Martling, MD, PhD, discusses study results which found that adjuvant daily aspirin reduced the risk of colorectal cancer recurrence among patients with PI3K alterations.
Anna Martling, MD, PhD,...
01/28/2025
Oncology
Seth Wander, MD, PhD; Kelly McCann, MD, PhD; Janice Lu, MD, PhD; Megan Kruse, MD
Videos
01/03/2025
Seth Wander, MD; Kelly McCann, MD, PhD; Janice Lu, MD, PhD; Megan Kruse, MD
In this video, a panel of experts discuss PIK3CA-mutant metastatic breast cancer, including the newest data on inavolisib from the INAVO120 trial.
In this video, a panel of experts discuss PIK3CA-mutant metastatic breast cancer, including the newest data on inavolisib from the INAVO120 trial.
In this video, a panel of...
01/03/2025
Oncology
Seth Wander, MD, PhD; Kelly McCann, MD, PhD; Janice Lu, MD, PhD; Megan Kruse, MD
Videos
01/03/2025
Seth Wander, MD; Kelly McCann, MD, PhD; Janice Lu, MD, PhD; Megan Kruse, MD
In this video, a panel of experts discuss PIK3CA-mutant metastatic breast cancer, including the agents targeting PI3K signaling.
In this video, a panel of experts discuss PIK3CA-mutant metastatic breast cancer, including the agents targeting PI3K signaling.
In this video, a panel of...
01/03/2025
Oncology
Seth Wander, MD, PhD; Kelly McCann, MD, PhD; Janice Lu, MD, PhD; Megan Kruse, MD
Videos
01/02/2025
Seth Wander, MD; Kelly McCann, MD, PhD; Janice Lu, MD, PhD; Megan Kruse, MD
In this video, a panel of experts discuss PIK3CA-mutant metastatic breast cancer, including an overview of the PI3 kinase pathway in cancer.
In this video, a panel of experts discuss PIK3CA-mutant metastatic breast cancer, including an overview of the PI3 kinase pathway in cancer.
In this video, a panel of...
01/02/2025
Oncology
Alberto Montero, MD, UH Seidman Cancer Center
Videos
10/17/2024
Alberto Montero, MD
Alberto Montero, MD, discusses phase 1/2 study results which demonstrated that STX-478 shows promise in patients with heavily pre-treated PI3Kα-mutated solid tumors.
Alberto Montero, MD, discusses phase 1/2 study results which demonstrated that STX-478 shows promise in patients with heavily pre-treated PI3Kα-mutated solid tumors.
Alberto Montero, MD, discusses...
10/17/2024
Oncology
Demetria Smith-Graziani, MD, MPH, Winship Cancer Institute
Videos
09/24/2024
Demetria J. Smith-Graziani, MD, MPH
Demetria Smith-Graziani, MD, MPH, describes the currently enrolling and ongoing INAVO121 trial, evaluating inavolisib vs alpelisib, both in combination with fulvestrant, for patients with PIK3CA-mutated, hormone receptor-positive,...
Demetria Smith-Graziani, MD, MPH, describes the currently enrolling and ongoing INAVO121 trial, evaluating inavolisib vs alpelisib, both in combination with fulvestrant, for patients with PIK3CA-mutated, hormone receptor-positive,...
Demetria Smith-Graziani, MD,...
09/24/2024
Oncology
Heather McArthur, MD
Videos
09/16/2024
Heather McArthur, MD, discusses results from the phase 3 CAPItello-290 trial which evaluated capivasertib plus paclitaxel as first-line treatment for patients with metastatic triple-negative breast cancer.
Heather McArthur, MD, discusses results from the phase 3 CAPItello-290 trial which evaluated capivasertib plus paclitaxel as first-line treatment for patients with metastatic triple-negative breast cancer.
Heather McArthur, MD, discusses...
09/16/2024
Oncology
Demetria Smith-Graziani, MD, MPH, Winship Cancer Institute
Videos
09/03/2024
Demetria J. Smith-Graziani, MD, MPH
Demetria Smith-Graziani, MD, MPH, shares insights from the results of the phase 3 INAVO120 study, evaluating the addition of inavolisib to palbociclib and fulvestrant for patients with PIK3CA-mutated, HR-positive, HER2-negative advanced...
Demetria Smith-Graziani, MD, MPH, shares insights from the results of the phase 3 INAVO120 study, evaluating the addition of inavolisib to palbociclib and fulvestrant for patients with PIK3CA-mutated, HR-positive, HER2-negative advanced...
Demetria Smith-Graziani, MD,...
09/03/2024
Oncology
Kenneth Aldape, MD
Videos
11/18/2026
Kenneth Aldape, MD, discusses advances in artificial intelligence-assisted tumor diagnosis, highlighting DNA methylation profiling, histopathology-based prediction of epigenomic signatures, and improved pathologist performance with artificial...
Kenneth Aldape, MD, discusses advances in artificial intelligence-assisted tumor diagnosis, highlighting DNA methylation profiling, histopathology-based prediction of epigenomic signatures, and improved pathologist performance with artificial...
Kenneth Aldape, MD, discusses...
11/18/2026
Oncology
Marcelo V. Negrao, MD
Videos
11/17/2026
Marcelo Negrao, MD
Marcelo V. Negrao, MD, discusses updated findings from the LOXO-RAS-20001 and SUNRAY-01 trials, presented at the 2026 European Society for Medical Oncology (ESMO) Congress. The integrated analysis evaluated olomorasib, a KRAS G12C inhibitor,...
Marcelo V. Negrao, MD, discusses updated findings from the LOXO-RAS-20001 and SUNRAY-01 trials, presented at the 2026 European Society for Medical Oncology (ESMO) Congress. The integrated analysis evaluated olomorasib, a KRAS G12C inhibitor,...
Marcelo V. Negrao, MD, discusses...
11/17/2026
Oncology
Essential Thrombocythemia (ET) Management: A Quiz Journey
11/16/2026
John Mascarenhas, MD
Consider how SURPASS-ET findings may inform next-line treatment discussions for patients with essential thrombocythemia.
Consider how SURPASS-ET findings may inform next-line treatment discussions for patients with essential thrombocythemia.
Consider how SURPASS-ET findings...
11/16/2026
Oncology
Essential Thrombocythemia (ET) Management: A Quiz Journey
11/16/2026
John Mascarenhas, MD
Assess your understanding of how hydroxyurea resistance and intolerance are distinguished in essential thrombocythemia.
Assess your understanding of how hydroxyurea resistance and intolerance are distinguished in essential thrombocythemia.
Assess your understanding of how...
11/16/2026
Oncology
Essential Thrombocythemia (ET) Management: A Quiz Journey
11/16/2026
John Mascarenhas, MD
Review a brief case presentation of a patient with essential thrombocythemia and apply your knowledge of risk assessment.
Review a brief case presentation of a patient with essential thrombocythemia and apply your knowledge of risk assessment.
Review a brief case presentation...
11/16/2026
Oncology
Essential Thrombocythemia (ET) Management: A Quiz Journey
11/16/2026
John Mascarenhas, MD
Test your understanding of the elements that make up a comprehensive assessment of essential thrombocythemia.
Test your understanding of the elements that make up a comprehensive assessment of essential thrombocythemia.
Test your understanding of the...
11/16/2026
Oncology
Oncology Learning Network Live Daily
11/16/2026
Beth Faiman, CNP, PhD
12/15/26: Chronic Lymphocytic Leukemia | Myeloproliferative Neoplasms | Multiple Myeloma
12/15/26: Chronic Lymphocytic Leukemia | Myeloproliferative Neoplasms | Multiple Myeloma
12/15/26: Chronic Lymphocytic...
11/16/2026
Oncology
Oncology Learning Network Live Daily
11/16/2026
John Mascarenhas, MD
12/14/26: Leukemia | Lymphoma | Multiple Myeloma | Transplant
12/14/26: Leukemia | Lymphoma | Multiple Myeloma | Transplant
12/14/26: Leukemia | Lymphoma |...
11/16/2026
Oncology
Oncology Learning Network Live Daily
11/16/2026
C. Ola Landgren, MD, PhD; Naval G. Daver
12/13/26: Hematologic Malignancies | Multiple Myeloma | CAR T and T-Cell Engagers
12/13/26: Hematologic Malignancies | Multiple Myeloma | CAR T and T-Cell Engagers
12/13/26: Hematologic...
11/16/2026
Oncology
Oncology Learning Network Live Daily
11/16/2026
This expert-led livestream provides real-time interpretation of emerging ASH 2026 data, with a focus on how new findings may influence clinical practice and treatment decision-making.
This expert-led livestream provides real-time interpretation of emerging ASH 2026 data, with a focus on how new findings may influence clinical practice and treatment decision-making.
This expert-led livestream...
11/16/2026
Oncology
OLN

PIK3CA

ALIASES

Phosphatidylinositol 3-kinase catalytic subunit

References

PIK3CA (phosphatidylinositol 3-kinase catalytic subunit) is an oncogene that encodes one piece (a subunit) of an enzyme called phosphatidylinositol 3-kinase (PI3-Kinase).1 PIK3CA plays a role in the control of cell growth, cell survival, and cell migration. Mutations in the PIK3CA gene can lead to uncontrolled cell growth and contribute to the proliferation and progression of cancer.2 

The PI3-Kinase pathway is one of many signaling pathways that are important for cell growth, transformation, adhesion, apoptosis, survival and invasion.3 PI3-Kinases are heterodimeric lipid kinases composed of catalytic and adaptor/regulatory subunits encoded by separate genes and alternative splicing. In the case of oncogenes, including PIK3CA, genetic changes such as a mutation can result in a cellular state whereby the PIK3CA gene product is constantly activated. Ultimately, this contributes toward uncontrolled cellular growth and other features that are the hallmarks of cancer.1

Gene amplifications, deletions and more recently, somatic missense mutations in the PIK3CA gene have been reported in many human cancer types including cancers of the colon, breast, brain, liver, stomach and lung. These somatic missense mutations were proposed to increase the kinase activity of PIK3CA contributing to cellular transformation.3

PIK3CA mutations are found in 20% to 25% of colon cancers and 10% of rectal cancers. In addition to colorectal cancer, PIK3CA oncogene mutations are involved in several human cancers including breast cancer, ovarian cancer, and non-small cell lung cancer (NSCLC).2

Understanding the Role of PIK3CA

News

Conference Coverage
12/03/2024
Allison Casey
According to a phase 1/2 study, the PI3K-alpha inhibitor, STX-478, showed promise among patients with PIK3CA-mutant solid tumors and/or HR-positive, HER2-negative breast cancer.
According to a phase 1/2 study, the PI3K-alpha inhibitor, STX-478, showed promise among patients with PIK3CA-mutant solid tumors and/or HR-positive, HER2-negative breast cancer.
According to a phase 1/2 study,...
12/03/2024
Oncology
Conference Coverage
12/03/2024
Allison Casey
In the PIKASSO-01 trial, LOXO-783 demonstrated a proof of mutant selectivity among patients with PIK3CA H1047R-mutant solid tumors. However, the rate of diarrhea prevented the determination of an optimal preclinical dose.
In the PIKASSO-01 trial, LOXO-783 demonstrated a proof of mutant selectivity among patients with PIK3CA H1047R-mutant solid tumors. However, the rate of diarrhea prevented the determination of an optimal preclinical dose.
In the PIKASSO-01 trial,...
12/03/2024
Oncology
News
11/05/2024
Allison Casey
According to a single-center cohort study, there was a substantial overall survival disparity, with differing frequencies of driver gene variations, by race and ethnicity.
According to a single-center cohort study, there was a substantial overall survival disparity, with differing frequencies of driver gene variations, by race and ethnicity.
According to a single-center...
11/05/2024
Oncology
News
10/31/2024
A multi-gene target panel NGS assay was found to be feasible and accurate when detecting mutations in patients with advanced HR-positive, HER2-negative breast cancer.
A multi-gene target panel NGS assay was found to be feasible and accurate when detecting mutations in patients with advanced HR-positive, HER2-negative breast cancer.
A multi-gene target panel NGS...
10/31/2024
Oncology
FDA Approval
10/10/2024
Allison Casey
The FDA has approved inavolisib, with palbociclib and fulvestrant for patients with endocrine-resistant, PIK3CA-mutated HR-positive, HER2-negative locally advanced or metastatic breast cancer.
The FDA has approved inavolisib, with palbociclib and fulvestrant for patients with endocrine-resistant, PIK3CA-mutated HR-positive, HER2-negative locally advanced or metastatic breast cancer.
The FDA has approved inavolisib,...
10/10/2024
Oncology
News
10/02/2024
Allison Casey
The phase 3 SAKK 41/13 trial provides the first prospective data that there is a protective effect with adjuvant advil among patients with resected, PIK3CA-mutant colon cancer.
The phase 3 SAKK 41/13 trial provides the first prospective data that there is a protective effect with adjuvant advil among patients with resected, PIK3CA-mutant colon cancer.
The phase 3 SAKK 41/13 trial...
10/02/2024
Oncology
News
09/24/2024
Allison Casey
The ongoing INAVO121 trial is open for enrollment of patients with hormone receptor-positive, HER2-negative, PIK3CA-mutated locally advanced or metastatic breast cancer who progressed during or after a CDK4/6-inhibitor–based regimen.
The ongoing INAVO121 trial is open for enrollment of patients with hormone receptor-positive, HER2-negative, PIK3CA-mutated locally advanced or metastatic breast cancer who progressed during or after a CDK4/6-inhibitor–based regimen.
The ongoing INAVO121 trial is...
09/24/2024
Oncology
Conference Coverage
12/08/2023
Stephanie Holland
According to primary analysis results from the phase 3 INAVO120 trial, the addition of inavolisib to palbociclib plus fulvestrant significantly improved investigator-assessed progression-free survival in PIK3CA-mutated, hormone...
According to primary analysis results from the phase 3 INAVO120 trial, the addition of inavolisib to palbociclib plus fulvestrant significantly improved investigator-assessed progression-free survival in PIK3CA-mutated, hormone...
According to primary analysis...
12/08/2023
Oncology
News
11/18/2026
Stephanie Holland
Results from a prospective study demonstrated that longitudinal tumor-naïve multimodal circulating cell-free DNA minimal residual disease monitoring stratified recurrence risk following curative-intent resection of non-small cell lung cancer...
Results from a prospective study demonstrated that longitudinal tumor-naïve multimodal circulating cell-free DNA minimal residual disease monitoring stratified recurrence risk following curative-intent resection of non-small cell lung cancer...
Results from a prospective study...
11/18/2026
Oncology
News
11/18/2026
Stephanie Holland
Results from a deep learning study demonstrated high accuracy in classifying FGFR3::TACC3 fusion-positive non-small cell lung cancer using hematoxylin and eosin-stained whole-slide images, suggesting that artificial intelligence may identify...
Results from a deep learning study demonstrated high accuracy in classifying FGFR3::TACC3 fusion-positive non-small cell lung cancer using hematoxylin and eosin-stained whole-slide images, suggesting that artificial intelligence may identify...
Results from a deep learning...
11/18/2026
Oncology
News
11/18/2026
Stephanie Holland
Results from a health-related quality-of-life analysis of the phase 3 MANEUVER trial demonstrated sustained improvements in patient-reported health status with pimicotinib in patients with tenosynovial giant cell tumor, with benefits...
Results from a health-related quality-of-life analysis of the phase 3 MANEUVER trial demonstrated sustained improvements in patient-reported health status with pimicotinib in patients with tenosynovial giant cell tumor, with benefits...
Results from a health-related...
11/18/2026
Oncology
News
11/18/2026
Stephanie Holland
Updated 2-year results from the phase 3 MANEUVER trial demonstrated sustained improvements in pain, stiffness, range of motion, and physical function with pimicotinib in patients with tenosynovial giant cell tumor, alongside durable tumor...
Updated 2-year results from the phase 3 MANEUVER trial demonstrated sustained improvements in pain, stiffness, range of motion, and physical function with pimicotinib in patients with tenosynovial giant cell tumor, alongside durable tumor...
Updated 2-year results from the...
11/18/2026
Oncology
News
11/18/2026
Stephanie Holland
Results from a clinical validation study demonstrated that cell-free DNA methylation-based fusion epigenotyping detected non-EML4-ALK fusions in non-small cell lung cancer with high sensitivity and specificity, supporting its potential to...
Results from a clinical validation study demonstrated that cell-free DNA methylation-based fusion epigenotyping detected non-EML4-ALK fusions in non-small cell lung cancer with high sensitivity and specificity, supporting its potential to...
Results from a clinical...
11/18/2026
Oncology
News
11/17/2026
Stephanie Holland
Updated results from the phase 2 FIREFLY-1 trial demonstrated prolonged treatment-free intervals with tovorafenib in relapsed or refractory BRAF-altered pediatric low-grade glioma, with most patients entering observation remaining off therapy...
Updated results from the phase 2 FIREFLY-1 trial demonstrated prolonged treatment-free intervals with tovorafenib in relapsed or refractory BRAF-altered pediatric low-grade glioma, with most patients entering observation remaining off therapy...
Updated results from the phase 2...
11/17/2026
Oncology
News
11/17/2026
Stephanie Holland
Results from a biomarker analysis of the phase 3 INDIGO trial demonstrated improved progression-free survival with vorasidenib across baseline IDH variant allele frequency subgroups in patients with grade 2 IDH-mutant glioma, supporting...
Results from a biomarker analysis of the phase 3 INDIGO trial demonstrated improved progression-free survival with vorasidenib across baseline IDH variant allele frequency subgroups in patients with grade 2 IDH-mutant glioma, supporting...
Results from a biomarker...
11/17/2026
Oncology
News
11/17/2026
Emily Estrada
Updated American Cancer Society prostate cancer screening guidelines recommend regular PSA-based testing for average-risk patients and earlier, more frequent screening for higher-risk patients, emphasizing early detection, confirmatory...
Updated American Cancer Society prostate cancer screening guidelines recommend regular PSA-based testing for average-risk patients and earlier, more frequent screening for higher-risk patients, emphasizing early detection, confirmatory...
Updated American Cancer Society...
11/17/2026
Oncology
FDA Approval
11/16/2026
Stephanie Holland
Based on results from the evERA Breast Cancer trial, the FDA has approved giredestrant plus everolimus for previously treated patients with ER-positive, HER2-negative, ESR1-mutated advanced breast cancer, demonstrating improved...
Based on results from the evERA Breast Cancer trial, the FDA has approved giredestrant plus everolimus for previously treated patients with ER-positive, HER2-negative, ESR1-mutated advanced breast cancer, demonstrating improved...
Based on results from the evERA...
11/16/2026
Oncology
FDA Approval
11/13/2026
Emily Estrada
Based on results from the phase 3 VOLGA trial, the FDA has approved neoadjuvant durvalumab plus enfortumab vedotin followed by adjuvant durvalumab for patients with muscle-invasive bladder cancer who are ineligible for or have refused...
Based on results from the phase 3 VOLGA trial, the FDA has approved neoadjuvant durvalumab plus enfortumab vedotin followed by adjuvant durvalumab for patients with muscle-invasive bladder cancer who are ineligible for or have refused...
Based on results from the phase...
11/13/2026
Oncology

Quizzes

Quiz
09/25/2024
Do you know what the progression-free survival was for the inavolisib arm in the INAVO120 trial? Test your knowledge with our quick quiz.
Do you know what the progression-free survival was for the inavolisib arm in the INAVO120 trial? Test your knowledge with our quick quiz.
Do you know what the...
09/25/2024
Oncology
Quiz
09/25/2024
Do you know what percentage of patients with hormone receptor-positive, HER2-negative breast cancer have a PIK3CA mutation? Take our quick quiz to find out!
Do you know what percentage of patients with hormone receptor-positive, HER2-negative breast cancer have a PIK3CA mutation? Take our quick quiz to find out!
Do you know what percentage of...
09/25/2024
Oncology
Essential Thrombocythemia (ET) Management: A Quiz Journey
11/16/2026
John Mascarenhas, MD
Consider how SURPASS-ET findings may inform next-line treatment discussions for patients with essential thrombocythemia.
Consider how SURPASS-ET findings may inform next-line treatment discussions for patients with essential thrombocythemia.
Consider how SURPASS-ET findings...
11/16/2026
Oncology
Essential Thrombocythemia (ET) Management: A Quiz Journey
11/16/2026
John Mascarenhas, MD
Assess your understanding of how hydroxyurea resistance and intolerance are distinguished in essential thrombocythemia.
Assess your understanding of how hydroxyurea resistance and intolerance are distinguished in essential thrombocythemia.
Assess your understanding of how...
11/16/2026
Oncology
Essential Thrombocythemia (ET) Management: A Quiz Journey
11/16/2026
John Mascarenhas, MD
Review a brief case presentation of a patient with essential thrombocythemia and apply your knowledge of risk assessment.
Review a brief case presentation of a patient with essential thrombocythemia and apply your knowledge of risk assessment.
Review a brief case presentation...
11/16/2026
Oncology
Essential Thrombocythemia (ET) Management: A Quiz Journey
11/16/2026
John Mascarenhas, MD
Test your understanding of the elements that make up a comprehensive assessment of essential thrombocythemia.
Test your understanding of the elements that make up a comprehensive assessment of essential thrombocythemia.
Test your understanding of the...
11/16/2026
Oncology
Quiz
10/08/2026
Test your knowledge of real-world outcomes with nirogacestat in young adults with desmoid tumors, including disease control, symptom improvement, and treatment-related toxicity observed in a retrospective, single-institution study.
Test your knowledge of real-world outcomes with nirogacestat in young adults with desmoid tumors, including disease control, symptom improvement, and treatment-related toxicity observed in a retrospective, single-institution study.
Test your knowledge of...
10/08/2026
Oncology
Quiz
06/19/2026
What was the effect of pegylated liposomal doxorubicin (PLD) on progression-free survival compared with placebo in patients with advanced or refractory desmoid tumors?
What was the effect of pegylated liposomal doxorubicin (PLD) on progression-free survival compared with placebo in patients with advanced or refractory desmoid tumors?
What was the effect of pegylated...
06/19/2026
Oncology
Quiz
06/19/2026
According to exploratory biomarker results from the phase 3 SKYSCRAPER-02C trial, which tumor characteristics were associated with a potentially greater benefit from tiragolumab-based therapy in patients with ES-SCLC?
According to exploratory biomarker results from the phase 3 SKYSCRAPER-02C trial, which tumor characteristics were associated with a potentially greater benefit from tiragolumab-based therapy in patients with ES-SCLC?
According to exploratory...
06/19/2026
Oncology
Quiz
06/19/2026
According to results from a phase 1 study evaluating eganelisib in heavily pretreated patients with relapsed or refractory acute myeloid leukemia and high-risk myelodysplastic syndromes, what evidence of antileukemic activity was reported...
According to results from a phase 1 study evaluating eganelisib in heavily pretreated patients with relapsed or refractory acute myeloid leukemia and high-risk myelodysplastic syndromes, what evidence of antileukemic activity was reported...
According to results from a...
06/19/2026
Oncology
Quiz
06/17/2026
Thank you for taking part in this brief survey. Your response will provide valuable insight into how clinicians manage polycythemia vera in clinical practice. 
Thank you for taking part in this brief survey. Your response will provide valuable insight into how clinicians manage polycythemia vera in clinical practice. 
Thank you for taking part in...
06/17/2026
Oncology
Quiz
06/09/2026
Which finding from the CADENZA trial supported the FDA approval of pivekimab sunirine for adult patients with blastic plasmacytoid dendritic cell neoplasms?
Which finding from the CADENZA trial supported the FDA approval of pivekimab sunirine for adult patients with blastic plasmacytoid dendritic cell neoplasms?
Which finding from the CADENZA...
06/09/2026
Oncology